Gastric CancerTAP-WELPASSNCT07452471
Comparison of the Postoperative Analgesic Effects of the Temperature-responsive Gel Mixed With Local Anesthetics Application and Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Gastrectomy
A study testing Ultrasound-guided Transversus Abdominis Plane (TAP) Block and Ropivacaine-Poloxamer 407 Hydrogel (Welpass®) in people with Gastric Cancer and Postoperative Pain, run by Gyeong-Jo Byeon, MD, PhD at 1 site in South Korea.
Trial summary
This study is a single-center, prospective, randomized controlled trial designed to compare two established postoperative analgesic strategies in adult patients undergoing laparoscopic gastrectomy under general anesthesia. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Gastric Cancer, Postoperative Pain
- What is being tested?
- Ultrasound-guided Transversus Abdominis Plane (TAP) Block and Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteSouth Korea
- Study dates
- 12 Feb 2026to 11 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 19 years or older undergoing laparoscopic gastrectomy under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
Who cannot join
- Known hypersensitivity or allergy to local anesthetics
- Presence of autoimmune disease or dermatologic conditions such as keloids
- Conversion from laparoscopic surgery to open surgery
- Pregnant women
- Chronic opioid use for persistent pain
- Inability to communicate effectively, making pain assessment difficult
- Refusal to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site
Yangsan Pusan National University Hospital
Yangsan, Gyeongsamnamdo, 50612
Gyeongjo Byun, MD, 82-10-5663-1713, byeongj@pusan.ac.kr
About this study
This study is a single-center, prospective, randomized controlled trial designed to compare two established postoperative analgesic strategies in adult patients undergoing laparoscopic gastrectomy under general anesthesia.
Effective pain control after laparoscopic gastrectomy is essential to promote early recovery, facilitate ambulation, reduce opioid consumption, and improve overall postoperative outcomes. Although minimally invasive techniques reduce surgical trauma, patients frequently experience moderate postoperative pain arising from abdominal wall incisions and trocar insertion sites.
Read more
This trial compares two analgesic approaches:
Ultrasound-guided bilateral transversus abdominis plane (TAP) block using 0.2% ropivacaine
Local application of a thermosensitive ropivacaine-poloxamer 407 hydrogel formulation (Welpass®) applied to the surgical site at the end of surgery
A total of 80 patients (age ≥19 years, American Society of Anesthesiologists physical status I-III) scheduled for elective laparoscopic gastrectomy will be enrolled at a single institution. Participants will be randomly assigned in a 1:1 ratio to either the TAP block group (n=40) or the hydrogel group (n=40).
In the TAP block group, 0.2% ropivacaine will be injected bilaterally between the internal oblique and transversus abdominis muscles under ultrasound guidance at the completion of surgery.
In the hydrogel group, a mixture of ropivacaine and poloxamer 407-based gel (Welpass®) will be prepared and applied locally to the surgical site, including the fascial plane and subcutaneous tissue, prior to wound closure.
All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia (PCA) according to institutional protocols.
The primary objective of the study is to compare postoperative pain intensity between the two groups. Pain will be assessed using the Visual Analog Scale (VAS) immediately upon arrival in the post-anesthesia care unit (PACU), just before PACU discharge, and at 12 and 24 hours after surgery.
Secondary outcomes include:
- Total PCA consumption within 48 hours
- Additional analgesic use (total dose and frequency)
- Time to first flatus
- Time to ambulation
- Length of hospital stay
- Incidence of postoperative nausea and vomiting (PONV)
Safety will be evaluated by monitoring adverse events, including signs of local anesthetic systemic toxicity or other serious complications. Both analgesic techniques involve medications and procedures that are widely used in routine clinical practice. The study uses approved drugs within standard dosing ranges and is conducted by experienced clinicians. If a serious adverse event suspected to be related to the intervention occurs, appropriate medical management will be provided immediately, and the Institutional Review Board (IRB) will be notified in accordance with regulatory requirements.
Participants may be withdrawn from the study if they experience a serious adverse reaction related to the intervention, if conversion to open surgery occurs, or if they choose to withdraw consent.
The aim of this study is to determine whether local application of sustained-release ropivacaine hydrogel provides analgesic efficacy comparable or superior to ultrasound-guided TAP block. The findings may help identify an effective and safe postoperative pain management strategy for patients undergoing laparoscopic gastrectomy and contribute to optimizing multimodal analgesia protocols in minimally invasive gastric surgery.
- Conditions
- Gastric Cancer, Postoperative Pain
- Being tested
- Ultrasound-guided Transversus Abdominis Plane (TAP) Block, Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)
- Medical subject headings
- Stomach Neoplasms, Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound-guided Transversus Abdominis Plane (TAP) BlockProcedure or surgery
Bilateral ultrasound-guided injection of 0.2% ropivacaine between the internal oblique and transversus abdominis muscles at the end of surgery
Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)Drug
Local application of a thermosensitive hydrogel containing ropivacaine and poloxamer 407 to the fascial and subcutaneous layers at the surgical site prior to wound closure
| Study group | Role | What they receive |
|---|---|---|
| TAP Block Group | Active comparator | Participants receive bilateral ultrasound-guided transversus abdominis plane (TAP) block with 0.2% ropivacaine at the completion of laparoscopic gastrectomy. Standardized general anesthesia and postoperative patient-controlled analgesia (PCA) are provided Receives: Procedure: Ultrasound-guided Transversus Abdominis Plane (TAP) Block |
| Ropivacaine-Poloxamer Hydrogel Group | Experimental | Participants receive local application of ropivacaine-poloxamer 407 thermosensitive hydrogel (Welpass®) at the surgical site following laparoscopic gastrectomy. Standardized general anesthesia and postoperative PCA are provided Receives: Drug: Ropivacaine-Poloxamer 407 Hydrogel (Welpass®) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Pain Intensity
Postoperative pain intensity measured using the Visual Analog Scale (VAS, 0-10) immediately upon arrival in the post-anesthesia care unit (PACU) and just before PACU discharge. The VAS ranges from 0 (no pain) to 10 (worst imaginable pain). Mean pain scores will be compared between the two groups
Measured: postoperative period(immediately upon arrival in PACU, at PACU discharge, 12,24 hours after surgery)
Secondary outcomes (7)
Total Patient-Controlled Analgesia (PCA) Consumption
Total cumulative dose of intravenous patient-controlled analgesia administered during the first 48 hours after surgery.
Measured: 48 hours postoperatively
Total Rescue Analgesic Dose
Total cumulative dose of additional rescue analgesics administered within 48 hours after surgery.
Measured: 48 hours postoperatively
Number of Rescue Analgesic Administrations
Total number of additional rescue analgesic administrations within 48 hours after surgery.
Measured: 48 hours postoperatively
Number of PONV Episodes
Total number of postoperative nausea and vomiting episodes occurring within 48 hours after surgery.
Measured: 48 hours postoperatively
Time to First Flatus
Time from the end of surgery to the first passage of flatus, measured in hours.
Measured: From the end of surgery until the first documented passage of flatus, assessed up to 7 days postoperatively
Time to First Ambulation
Time from the end of surgery to first ambulation, measured in hours.
Measured: From end of surgery to first ambulation, assessed up to 7 postoperative days
Length of Postoperative Hospital Stay
Duration of hospitalization from the date of surgery to the date of discharge, measured in days.
Measured: From date of surgery to date of discharge, assessed up to 30 days postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2026
- Study start12 Feb 2026 (estimated)
- Primary completion11 Feb 2027 (estimated)
- Study completion11 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gyeong-Jo Byeon, MD, PhD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Gyeong-Jo Byeon, MD, PhD, Pusan National University Yangsan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07452471
- Sponsor's protocol ID
- WELPASS-TAP
- Other IDs
- IRB 21-2026-002
- Acronym
- TAP-WELPASS
- Status last verified
- Feb 2026
- First submitted
- 20 Feb 2026
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data will not be shared due to institutional policies and restrictions outlined in the informed consent process. The study is a single-center clinical trial, and no plans for public data repository submission have been established
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Postoperative Analgesic Effects of the Temperature-responsive Gel Mixed With Local Anesthetics Application and Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Gastrectomy
- ClinicalTrials.gov ID
- NCT07452471
- Acronym / sponsor ID
- TAP-WELPASS / WELPASS-TAP
- Conditions
- Gastric Cancer, Postoperative Pain
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Gyeong-Jo Byeon, MD, PhDUniversity, hospital or other
- Study start
- 12 Feb 2026 (estimated)
- Primary completion
- 11 Feb 2027 (estimated)
- Study completion
- 11 Feb 2027 (estimated)
- First posted
- 5 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a single-center, prospective, randomized controlled trial designed to compare two established postoperative analgesic strategies in adult patients undergoing laparoscopic gastrectomy under general anesthesia.
Effective pain control after laparoscopic gastrectomy is essential to promote early recovery, facilitate ambulation, reduce opioid consumption, and improve overall postoperative outcomes. Although minimally invasive techniques reduce surgical trauma, patients frequently experience moderate postoperative pain arising from abdominal wall incisions and trocar insertion sites.
This trial compares two analgesic approaches:
Ultrasound-guided bilateral transversus abdominis plane (TAP) block using 0.2% ropivacaine
Local application of a thermosensitive ropivacaine-poloxamer 407 hydrogel formulation (Welpass®) applied to the surgical site at the end of surgery
A total of 80 patients (age ≥19 years, American Society of Anesthesiologists physical status I-III) scheduled for elective laparoscopic gastrectomy will be enrolled at a single institution. Participants will be randomly assigned in a 1:1 ratio to either the TAP block group (n=40) or the hydrogel group (n=40).
In the TAP block group, 0.2% ropivacaine will be injected bilaterally between the internal oblique and transversus abdominis muscles under ultrasound guidance at the completion of surgery.
In the hydrogel group, a mixture of ropivacaine and poloxamer 407-based gel (Welpass®) will be prepared and applied locally to the surgical site, including the fascial plane and subcutaneous tissue, prior to wound closure.
All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia (PCA) according to institutional protocols.
The primary objective of the study is to compare postoperative pain intensity between the two groups. Pain will be assessed using the Visual Analog Scale (VAS) immediately upon arrival in the post-anesthesia care unit (PACU), just before PACU discharge, and at 12 and 24 hours after surgery.
Secondary outcomes include:
- Total PCA consumption within 48 hours
- Additional analgesic use (total dose and frequency)
- Time to first flatus
- Time to ambulation
- Length of hospital stay
- Incidence of postoperative nausea and vomiting (PONV)
Safety will be evaluated by monitoring adverse events, including signs of local anesthetic systemic toxicity or other serious complications. Both analgesic techniques involve medications and procedures that are widely used in routine clinical practice. The study uses approved drugs within standard dosing ranges and is conducted by experienced clinicians. If a serious adverse event suspected to be related to the intervention occurs, appropriate medical management will be provided immediately, and the Institutional Review Board (IRB) will be notified in accordance with regulatory requirements.
Participants may be withdrawn from the study if they experience a serious adverse reaction related to the intervention, if conversion to open surgery occurs, or if they choose to withdraw consent.
The aim of this study is to determine whether local application of sustained-release ropivacaine hydrogel provides analgesic efficacy comparable or superior to ultrasound-guided TAP block. The findings may help identify an effective and safe postoperative pain management strategy for patients undergoing laparoscopic gastrectomy and contribute to optimizing multimodal analgesia protocols in minimally invasive gastric surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TAP Block Group | Active comparator | Procedure: Ultrasound-guided Transversus Abdominis Plane (TAP) BlockParticipants receive bilateral ultrasound-guided transversus abdominis plane (TAP) block with 0.2% ropivacaine at the completion of laparoscopic gastrectomy. Standardized general anesthesia and postoperative patient-controlled analgesia (PCA) are provided |
| Ropivacaine-Poloxamer Hydrogel Group | Experimental | Drug: Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)Participants receive local application of ropivacaine-poloxamer 407 thermosensitive hydrogel (Welpass®) at the surgical site following laparoscopic gastrectomy. Standardized general anesthesia and postoperative PCA are provided |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adults aged 19 years or older undergoing laparoscopic gastrectomy under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
Key exclusion criteria (7 listed)
- Known hypersensitivity or allergy to local anesthetics
- Presence of autoimmune disease or dermatologic conditions such as keloids
- Conversion from laparoscopic surgery to open surgery
- Pregnant women
- Chronic opioid use for persistent pain
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound-guided Transversus Abdominis Plane (TAP) BlockBilateral ultrasound-guided injection of 0.2% ropivacaine between the internal oblique and transversus abdominis muscles at the end of surgery | Procedure or surgery | TAP Block Group |
| Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)Local application of a thermosensitive hydrogel containing ropivacaine and poloxamer 407 to the fascial and subcutaneous layers at the surgical site prior to wound closure | Drug | Ropivacaine-Poloxamer Hydrogel Group |
Primary outcome
Postoperative Pain Intensity
Time frame: postoperative period(immediately upon arrival in PACU, at PACU discharge, 12,24 hours after surgery)
Postoperative pain intensity measured using the Visual Analog Scale (VAS, 0-10) immediately upon arrival in the post-anesthesia care unit (PACU) and just before PACU discharge. The VAS ranges from 0 (no pain) to 10 (worst imaginable pain). Mean pain scores will be compared between the two groups
7 secondary outcomes
Total Patient-Controlled Analgesia (PCA) Consumption
Time frame: 48 hours postoperatively
Total Rescue Analgesic Dose
Time frame: 48 hours postoperatively
Number of Rescue Analgesic Administrations
Time frame: 48 hours postoperatively
Number of PONV Episodes
Time frame: 48 hours postoperatively
Time to First Flatus
Time frame: From the end of surgery until the first documented passage of flatus, assessed up to 7 days postoperatively
Time to First Ambulation
Time frame: From end of surgery to first ambulation, assessed up to 7 postoperative days
Length of Postoperative Hospital Stay
Time frame: From date of surgery to date of discharge, assessed up to 30 days postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data will not be shared due to institutional policies and restrictions outlined in the informed consent process. The study is a single-center clinical trial, and no plans for public data repository submission have been established
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound-guided Transversus Abdominis Plane (TAP) Block and Ropivacaine-Poloxamer 407 Hydrogel (Welpass®) in people with Gastric Cancer and Postoperative Pain, run by Gyeong-Jo Byeon, MD, PhD at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gyeong Jo Byun, MD (82-10-5663-1713, byeongj@pusan.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Pain Intensity (time frame: postoperative period(immediately upon arrival in PACU, at PACU discharge, 12,24 hours after surgery)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.